niacinamide has been researched along with Adrenal Cortex Cancer in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the in vitro study, sorafenib impaired the viability of H295R cells with dose-response and time-response relationships." | 6.77 | Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. ( Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M, 2012) |
| " In the in vitro study, sorafenib impaired the viability of H295R cells with dose-response and time-response relationships." | 2.77 | Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. ( Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berruti, A | 1 |
| Sperone, P | 1 |
| Ferrero, A | 1 |
| Germano, A | 1 |
| Ardito, A | 1 |
| Priola, AM | 1 |
| De Francia, S | 1 |
| Volante, M | 1 |
| Daffara, F | 1 |
| Generali, D | 1 |
| Leboulleux, S | 1 |
| Perotti, P | 1 |
| Baudin, E | 1 |
| Papotti, M | 1 |
| Terzolo, M | 1 |
| Mariniello, B | 1 |
| Rosato, A | 1 |
| Zuccolotto, G | 1 |
| Rubin, B | 1 |
| Cicala, MV | 1 |
| Finco, I | 1 |
| Iacobone, M | 1 |
| Frigo, AC | 1 |
| Fassina, A | 1 |
| Pezzani, R | 1 |
| Mantero, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines[NCT03257891] | Phase 2 | 25 participants (Anticipated) | Interventional | 2018-01-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
1 other study available for niacinamide and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Animals; Antineoplastic Combined Chemoth | 2012 |